Skip to content

Appropriateness of Hemostatic Agent Use in Cardiovascular Surgery (HAEMOVAX)

Evaluation of Appropriateness in the Use of Hemostatic Agents in Cardiovascular Surgery: A Mixed-Methods Single-Center Observational Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07699016
Acronym
HAEMOVAX
Enrollment
15
Registered
2026-07-13
Start date
2026-07-01
Completion date
2026-08-15
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Surgery, Cardiovascular Surgery, Hemostasis, Perioperative Bleeding, Vascular Surgery

Keywords

Hemostatic Agents, Surgical Hemostasis, Topical Hemostatic Agents, Perioperative Bleeding

Brief summary

Hemostatic agents are widely used in cardiac and vascular surgery to support intraoperative bleeding control. Despite their clinical relevance and substantial economic impact, little is known about real-world patterns of use, adherence to evidence-based recommendations, and the alignment between clinicians' perceived knowledge and actual decision-making. HAEMOVAX is a single-center mixed-methods observational study conducted at IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy. The study combines an anonymous survey of cardiovascular surgeons with a retrospective audit of institutional hemostatic agent consumption. The primary objective is to evaluate the appropriateness of hemostatic agent selection using a Knowledge-Practice Alignment Score (KPA-Score) derived from standardized clinical vignettes based on current EACTS and ESA recommendations. Secondary objectives include assessment of usage patterns, barriers to appropriate use, concordance between declared practice and real-world consumption, and opportunities for evidence-based standardization.

Detailed description

Hemostatic agents are routinely used in cardiac and vascular surgery to support local bleeding control and facilitate surgical hemostasis. Their use may influence several clinically relevant outcomes, including perioperative blood loss, transfusion requirements, operative time, reintervention for bleeding, and postoperative complications. In addition to their clinical implications, topical hemostatic agents represent a significant component of procedural costs in cardiovascular surgery. Despite their widespread use, evidence regarding real-world utilization patterns remains limited. Available literature is largely derived from industry-sponsored randomized trials designed to evaluate the efficacy of individual products in selected procedural settings. Consequently, little is known about how hemostatic agents are actually selected and utilized in routine clinical practice, the degree of adherence to contemporary evidence-based recommendations, and the potential discrepancy between clinicians' perceived knowledge and their decision-making in standardized clinical scenarios. Furthermore, many institutions lack formal protocols governing the selection of hemostatic agents according to surgical indication, bleeding severity, or patient-specific factors. This may contribute to substantial variability in practice patterns, inefficient resource allocation, and inconsistent application of current guideline recommendations. Understanding these factors is essential to support evidence-based standardization strategies and optimize both clinical and economic outcomes. The HAEMOVAX study is a single-center mixed-methods observational study conducted at IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy. The study consists of three complementary components: (1) an anonymous structured survey administered to cardiac and vascular surgeons; (2) a retrospective audit of institutional hemostatic agent consumption derived from pharmacy and operating room supply records; and (3) a qualitative thematic analysis of narrative clinical cases reported by participants. The primary objective is to evaluate the appropriateness of hemostatic agent selection using the Knowledge-Practice Alignment Score (KPA-Score). The KPA-Score is calculated from responses to five standardized clinical vignettes representing common cardiovascular surgical scenarios. Appropriateness is defined as concordance between the participant's selected hemostatic strategy and recommendations derived from contemporary EACTS and ESA guidelines. Individual KPA-Scores range from 0% to 100%, with scores of 60% or greater considered indicative of appropriate hemostatic agent selection. Secondary objectives include characterization of self-reported utilization patterns of hemostatic agents, assessment of perceived barriers to appropriate use, evaluation of concordance between declared practice and institutional consumption data, estimation of opportunities for evidence-based standardization, and identification of factors associated with lower KPA-Scores. Qualitative analysis will be performed to explore themes not fully captured by structured survey questions, including decision-making processes, institutional barriers, and perceptions regarding product effectiveness and availability. All attending surgeons, fellows, and residents affiliated with the Cardiac Surgery and Vascular Surgery Units will be eligible to participate. Survey responses will be collected anonymously. Consumption data will be analyzed in aggregated form at the unit level. No patient-identifiable information will be collected or analyzed. Study findings are expected to provide a comprehensive assessment of the appropriateness of hemostatic agent use within a high-volume cardiovascular surgical center and to identify opportunities for educational interventions, institutional protocol development, resource optimization, and evidence-based standardization of clinical practice.

Interventions

OTHERobservational study

Cross-sectional structured survey assessing knowledge-practice alignment in the use of hemostatic agents, combined with retrospective institutional audit of product consumption. No therapeutic or experimental intervention is administered.

Sponsors

University of Milan
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Physicians with a surgical role in the Departments of Cardiac Surgery or Vascular Surgery at IRCCS Galeazzi-Sant'Ambrogio, Milan Including attending surgeons, consultant surgeons, and surgical residents * Active participation in cardiovascular operative procedures during the study period (or within the preceding 12 months) * Employment at the study institution at the time of survey administration Willingness to participate and complete the anonymous structured questionnaire

Exclusion criteria

* Non-surgical healthcare personnel (e.g., nurses, anesthesiologists, administrative staff, or allied health professionals) * Surgeons not involved in operative cardiovascular practice during the study period * External collaborators or visiting surgeons without regular clinical activity at the institution * Individuals who do not provide informed consent for participation in the anonymous survey * Questionnaires with missing or incomplete vignette responses preventing calculation of the KPA-Score

Design outcomes

Primary

MeasureTime frameDescription
Proportion of participants achieving a Knowledge-Practice Alignment Score (KPA-Score) ≥60%BaselineThe Knowledge-Practice Alignment Score (KPA-Score) is a study-defined measure representing the percentage of guideline-concordant responses across five standardized clinical vignettes assessing hemostatic agent selection. Scores range from 0% to 100%, with higher scores indicating greater concordance with current European Association for Cardio-Thoracic Surgery (EACTS) and European Society of Anaesthesiology and Intensive Care (ESAIC) recommendations. The reported outcome is the percentage of participants achieving a KPA-Score of at least 60%.

Secondary

MeasureTime frameDescription
Self-perceived knowledge of hemostatic agent selectionBaselineParticipants' self-perceived knowledge regarding hemostatic agent selection, assessed using a 5-point Likert scale (1 = very low knowledge; 5 = very high knowledge).
Knowledge-Practice Alignment Score (KPA-Score)BaselinePercentage of guideline-concordant responses across five standardized clinical vignettes assessing hemostatic agent selection. Scores range from 0% to 100%, with higher scores indicating greater concordance with current European Association for Cardio-Thoracic Surgery (EACTS) and European Society of Anaesthesiology and Intensive Care (ESAIC) recommendations.
Correlation between self-perceived knowledge and Knowledge-Practice Alignment ScoreBaselineCorrelation between participants' self-perceived knowledge (5-point Likert scale) and their Knowledge-Practice Alignment Score (0%-100%), assessed using Spearman's rank correlation coefficient (ρ).
Concordance between declared and actual hemostatic agent usebaselineAgreement between participants' self-reported patterns of hemostatic agent use and institutional pharmacy dispensing data during the 12 months preceding survey administration, assessed using Cohen's kappa coefficient (κ).
Distribution of hemostatic agent selection across standardized clinical vignettesBaselinePercentage of participants selecting each hemostatic agent category for each of the five standardized clinical vignettes.
Perceived barriers to appropriate hemostatic agent selectionBaselinePercentage of participants reporting each predefined institutional, clinical, or logistical barrier to appropriate hemostatic agent selection, as assessed using the HAEMOVAX structured survey questionnaire.

Countries

Italy

Contacts

CONTACTLuca Galassi, MD
luca.galassi@unimi.it+393458013083

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026